Cargando…

Eligibility for Bevacizumab as an Independent Prognostic Factor for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study

BACKGROUND: Bevacizumab requires some unique eligibility criteria, such as absence of hemoptysis and major blood vessel invasion by the tumor. The prognostic impact of these bevacizumab-specific criteria has not been evaluated. METHODS: Patients with stage IIIB/IV, non-squamous non-small cell lung c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takagi, Yusuke, Toriihara, Akira, Nakahara, Yoshiro, Yomota, Makiko, Okuma, Yusuke, Hosomi, Yukio, Shibuya, Masahiko, Okamura, Tatsuru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608561/ https://www.ncbi.nlm.nih.gov/pubmed/23555751 http://dx.doi.org/10.1371/journal.pone.0059700

Ejemplares similares

Noninvasive monitoring of the genetic evolution of EGFR-mutant non-small-cell lung cancer by analyzing circulating tumor DNA during combination chemotherapy with gefitinib and pemetrexed or S-1
por: Nakahara, Yoshiro, et al.
Publicado: (2016)

Retrospective analysis of unknown primary cancers with malignant pleural effusion at initial diagnosis
por: Ebata, Takahiro, et al.
Publicado: (2015)

A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer
por: Kato, Yasuhiro, et al.
Publicado: (2019)

Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma
por: Okuma, Yusuke, et al.
Publicado: (2016)

Erratum to: Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma
por: Okuma, Yusuke, et al.
Publicado: (2016)

Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014
por: Takagi, Yusuke, et al.
Publicado: (2015)

Alectinib for choroidal metastasis in a patient with crizotinib-resistant ALK rearranged positive non-small cell lung cancer
por: Okuma, Yusuke, et al.
Publicado: (2015)

Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy
por: Okuma, Yusuke, et al.
Publicado: (2014)

Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis
por: Fukuda, Akito, et al.
Publicado: (2022)

Small-cell lung cancer with a rare epidermal growth factor receptor gene mutation showing “wax-and-wane” transformation
por: Takagi, Yusuke, et al.
Publicado: (2013)

Clinicopathological analysis of thymic malignancies with a consistent retrospective database in a single institution: from Tokyo Metropolitan Cancer Center
por: Okuma, Yusuke, et al.
Publicado: (2014)

Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer
por: Yomota, Makiko, et al.
Publicado: (2021)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Lung cancer patients harboring epidermal growth factor receptor mutation among those infected by human immunodeficiency virus
por: Okuma, Yusuke, et al.
Publicado: (2014)

A case of diffuse pulmonary ossification
por: Yomota, Makiko, et al.
Publicado: (2021)

Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS , MET , FGFR , RET , BRAF , and HER2 alterations
por: Uehara, Yuji, et al.
Publicado: (2022)

Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016
por: Ikeda, Satoshi, et al.
Publicado: (2018)

Multicenter, single-arm phase II study of modified carboplatin/nab-paclitaxel in untreated performance status 2 patients with advanced non-small cell lung cancer: TORG1426
por: Ichikawa, Yasuko, et al.
Publicado: (2023)

Association between chronic bacterial airway infection and prognosis of bronchiolitis obliterans syndrome after hematopoietic cell transplantation
por: Yomota, Makiko, et al.
Publicado: (2019)

Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy
por: Uehara, Yuji, et al.
Publicado: (2022)

Clinical outcome of thymic lymphoepithelioma-like carcinoma: Case report of a 14-year-old male
por: SEKIHARA, KUNIKO, et al.
Publicado: (2014)

Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review
por: Hashimoto, Kana, et al.
Publicado: (2016)

Pulmonary amyloidosis mimicking prostate cancer metastasis
por: Natsume, Soichiro, et al.
Publicado: (2015)

Crucial role of treatment with palliative intent for a patient with advanced thymic carcinoma
por: NAGAMATA, MAKOTO, et al.
Publicado: (2014)

Osseous oligometastases from thymic carcinoma: a case report suggesting the effectiveness of palliative-intent radiotherapy treatment
por: Kashima, Jumpei, et al.
Publicado: (2016)

Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma
por: Watanabe, Kageaki, et al.
Publicado: (2021)

Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017
por: Nakahara, Yoshiro, et al.
Publicado: (2019)

Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study
por: Hosomi, Yukio, et al.
Publicado: (2022)

Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913
por: Nakahara, Yoshiro, et al.
Publicado: (2020)

Cancer Cachexia among Patients with Advanced Non-Small-Cell Lung Cancer on Immunotherapy: An Observational Study with Exploratory Gut Microbiota Analysis
por: Hakozaki, Taiki, et al.
Publicado: (2022)

Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer
por: Hamada, Shohei, et al.
Publicado: (2019)

Pneumothorax during Pazopanib Treatment in Patients with Soft-Tissue Sarcoma: Two Case Reports and a Review of the Literature
por: Nakahara, Yoshiro, et al.
Publicado: (2017)

Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma
por: Okuma, Yusuke, et al.
Publicado: (2020)

Tracheobronchial and Pulmonary Amyloidosis Mimicking Pulmonary Metastases in a Patient With Lung Adenocarcinoma
por: Uematsu, Mao, et al.
Publicado: (2020)

Bevacizumab Eligibility in Patients with Metastatic and Recurrent Cervical Cancer: A Retrospective Review
por: Skelton, William Paul, et al.
Publicado: (2018)

Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis
por: Xiao, Xian, et al.
Publicado: (2022)

Change of Cerebral Blood Flow After a Successful Pharmacological Treatment of Phantom Bite Syndrome: A Case Report
por: Umezaki, Yojiro, et al.
Publicado: (2019)

Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis
por: Kitadai, Rui, et al.
Publicado: (2022)

Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
por: YOKOI, TAKASHI, et al.
Publicado: (2014)

Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin(®)) in patients with advanced non-squamous non-small cell lung cancer
por: Li, Cheryl S. W., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0pm8014q7qciu1akjag46do91q